236 related articles for article (PubMed ID: 21647730)
21. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Marousi S; Travasarou M; Karageorgiou CE; Gheuens S; Koralnik IJ
Neurology; 2012 Nov; 79(21):2160; author reply 2160. PubMed ID: 23170016
[No Abstract] [Full Text] [Related]
22. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
Warnke C; Menge T; Hartung HP; Racke MK; Cravens PD; Bennett JL; Frohman EM; Greenberg BM; Zamvil SS; Gold R; Hemmer B; Kieseier BC; Stüve O
Arch Neurol; 2010 Aug; 67(8):923-30. PubMed ID: 20697042
[TBL] [Abstract][Full Text] [Related]
23. Natalizumab-induced progressive multifocal leukoencephalopathy.
Thaker AA; Schmitt SE; Pollard JR; Dubroff JG
Clin Nucl Med; 2014 Jul; 39(7):e365-6. PubMed ID: 24152618
[TBL] [Abstract][Full Text] [Related]
24. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
Ercan MB; Kocer B; Altiparmak T; Arslan I
Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206
[No Abstract] [Full Text] [Related]
25. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Tur C; Montalban X
Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
[No Abstract] [Full Text] [Related]
26. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
[TBL] [Abstract][Full Text] [Related]
27. Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.
Havla J; Hohlfeld R; Kümpfel T
J Neurol; 2014 Jan; 261(1):232-4. PubMed ID: 24276521
[No Abstract] [Full Text] [Related]
28. Deaths and disability from natalizumab are no longer tolerable: Commentary.
Hutchinson M
Mult Scler; 2012 Aug; 18(8):1073. PubMed ID: 22807472
[No Abstract] [Full Text] [Related]
29. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
Fernández O; García-Merino JA; Arroyo R; Álvarez-Cermeño JC; Izquierdo G; Saiz A; Olascoaga J; Rodríguez-Antigüedad A; Prieto JM; Oreja-Guevara C; Hernández MA; Moral E; Meca J; Montalbán X
Neurologia; 2015 Jun; 30(5):302-14. PubMed ID: 24360652
[TBL] [Abstract][Full Text] [Related]
30. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
Rispens T; Vennegoor A; Wolbink GJ; Polman CH; Killestein J
Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
[TBL] [Abstract][Full Text] [Related]
32. Natalizumab-associated progressive multifocal leukoencephalopathy.
Mancini N; Clementi M; Burioni R
N Engl J Med; 2012 Aug; 367(9):871-2; author reply 872. PubMed ID: 22931329
[No Abstract] [Full Text] [Related]
33. Natalizumab-associated progressive multifocal leukoencephalopathy.
Cervera C
N Engl J Med; 2012 Aug; 367(9):871; author reply 872. PubMed ID: 22931328
[No Abstract] [Full Text] [Related]
34. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
Kleinschmidt-DeMasters BK; Tyler KL
N Engl J Med; 2005 Jul; 353(4):369-74. PubMed ID: 15947079
[TBL] [Abstract][Full Text] [Related]
35. [New drugs; natalizumab].
van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881
[TBL] [Abstract][Full Text] [Related]
36. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
[TBL] [Abstract][Full Text] [Related]
37. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Hoepner R; Ahlbrecht J; Faissner S; Schneider R; Dahlhaus S; Adams O; Raab P; Lukas C; Chan A; Stangel M; Gold R
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1177-8. PubMed ID: 24700881
[No Abstract] [Full Text] [Related]
38. Natalizumab for multiple sclerosis: a complicated treatment.
Keegan BM
Lancet Neurol; 2011 Aug; 10(8):677-8. PubMed ID: 21777819
[No Abstract] [Full Text] [Related]
39. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
[TBL] [Abstract][Full Text] [Related]
40. Natalizumab for relapsing multiple sclerosis.
Tenser RB
N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
